|
|
Volumn 37, Issue 2, 2014, Pages 125-126
|
|
Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: Considerations for biosimilars"
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOSIMILAR AGENT;
OLIGOSACCHARIDE;
PROTEIN;
BIOTECHNOLOGY;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
HUMAN;
IMMUNE RESPONSE;
IMMUNOGENICITY;
LAW;
LETTER;
LICENSING;
PHARMACY;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROTEIN GLYCOSYLATION;
PROTEIN PROCESSING;
PROTEIN STRUCTURE;
RISK ASSESSMENT;
RISK MANAGEMENT;
BIOSIMILAR PHARMACEUTICALS;
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;
HUMANS;
PHARMACOVIGILANCE;
|
|
EID: 84897933491
PISSN: 01145916
EISSN: 11791942
Source Type: Journal
DOI: 10.1007/s40264-013-0130-y Document Type: Letter |
|
Times cited : (2)
|
|
References (6)
|
